Protalix BioTherapeutics (PLX) Cash & Equivalents Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Protalix BioTherapeutics | 192.04 Mn | 181.24 Mn | 29.62 Mn | -96.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.35% |
| Dec 31, 2025 | -96.45% |
| Sep 30, 2025 | -50.21% |
| Jun 30, 2025 | -23.52% |
| Mar 31, 2025 | -28.49% |
| Dec 31, 2024 | -16.39% |
| Sep 30, 2024 | 34.31% |
| Jun 30, 2024 | -51.44% |
| Mar 31, 2024 | -17.64% |
| Dec 31, 2023 | 38.12% |
| Sep 30, 2023 | 90.37% |
| Jun 30, 2023 | 285.72% |
| Mar 31, 2023 | 95.62% |
| Dec 31, 2022 | -56.11% |
| Sep 30, 2022 | 0.73% |
| Jun 30, 2022 | -63.13% |
| Mar 31, 2022 | -14.84% |
| Dec 31, 2021 | 113.44% |
| Sep 30, 2021 | -21.36% |
| Jun 30, 2021 | 599.61% |